The effect of DA-8159 on corpus cevernosal smooth muscle relaxation and penile erection in diabetic rabbits

Urological Research

Volumn 32, Issue 2, 2004, Pages 107-111

  Kang, Kyung Koo ^a   Choi, Seul Min ^a   Ahn, Gook Jun ^a   Kwon, Jong Won ^a   Kim, Won Bae ^a  

^a Dong A Pharmaceutical Company   (South Korea)

Author keywords

Corpus cavernosum smooth muscle relaxation; DA 8159; Diabetes mellitus; Penile erection

Indexed keywords

ALLOXAN; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; UDENAFIL;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; ERECTILE DYSFUNCTION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; SMOOTH MUSCLE RELAXATION; TREATMENT OUTCOME;

ANIMALS; AREA UNDER CURVE; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH; NITROPRUSSIDE; PENILE ERECTION; PENIS; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITORS; PYRIMIDINES; RABBITS; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 3142742352     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00240-003-0387-1     Document Type: Article

References (27)

1. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA (1989) Impaired neurogenic and endothelium mediated relaxation of penile smooth muscle from diabetic men with impotence. New Engl J Med 320:1025
2. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF (1980) The prevalence of diabetic impotence. Diabetologia 18:279
3. Murray FT, Wyss HU, Thomas RG, Spevack M, Glaros AG (1987) Gonadal dysfunction in diabetic men with organic impotence. J Clin Endocrinol Metabol 65:127
4. Utkan T, Yildirim MK, Yildirim S, Sarioglu Y (2001) Effects of the specific phosphodiesterase inhibitors on alloxan-induced diabetic rabbit cavernous tissue in vitro. Int J Impot Res 13:24
5. dp (type II) rats with erectile dysfunction. Endocrinol 136:5709
6. Kuan J, Brock G (2002) Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. Expert Opinion Investigational Drugs 11:1605
7. Price DE, Gingell JC, Gepi-Attee S, Wareham K, Yates P, Boolell M (1998) Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 15:821
8. Wagner G, Saenz de Tejada I (1998) Fortnightly review update on male erectile dysfunction. Brit Med Journal 316:678
9. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H (2002) Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 23:763
10. Pryor J (2002) Vardenafil: update on clinical experience. Int J Impot Res 14:S65
11. Eardley I, Cartledge J (2002) Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract 56:300
12. Doh H, Shin CY, Son M, Ko JI, Yoo M, Kim SH, Kim WB (2002) Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharmacol Res 25:873
13. Oh TY, Kang KK, Ahn BO, Yoo M, Kim WB (2000) Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharmacol Res 23:471
14. Azodzoi KM, Saenz de Tejada I (1992) Diabetes mellitus impairs neurogenic and endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 148:1587
15. Ayan S, Yildirim S, Ucar C, Sarioglu Y, Gultekin Y, Butuner C (1999) Corporal reactivity to adenosine and prostaglandin El in alloxan-induced diabetic rabbit corpus cavernosum, and the effect of insulin therapy. BJU Int 83:108
16. Dey J, Shepherd MD (2002) Evaluation and treatment of erectile dysfunction in men with diabetes mellitus. Mayo Clin Proc 77:276
17. Francis SH, Turko IV, Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1
18. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75:725
19. Juilfs DM, Soderling S, Burns F, Beavo JA (1999) Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol 135:67
20. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, Phillips SC (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci U S A 97:3702
21. Jeremy JY, Ballard SA, Naylor AM, Miller MA, Angelini GD (1997) Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 79:958
22. Corbin JD, Francis SH (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 274:13729
23. Gopal VK, Francis SH, Corbin JD (2001) Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem 268:3304
24. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47
25. Uckert S, Kuthe A, Stief CG, Jonas U (2001) Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 19:14
26. Hosogai N, Hamada K, Tomita M, Nagashima A, Takahashi T, Sekizawa T, Mizutani T, Urano Y, Kuroda A, Sawada K, Ozaki T, Seki J, Goto T (2001) FR226807: a potent and selective phosphodiesterase type 5 inhibitor. Eur J Pharmacol 428:295
27. Wallis RM, Corbin JD, Francis SH, Ellis P (1999) Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 83:3C